Tag:
central nervous system
Latest Headlines
Latest Headlines
Analysis: Grim stats on CNS drugs demand fresh approach to development
It's no secret that neuropsychiatric diseases like schizophrenia, depression and Alzheimer's present one of the toughest challenges to drug developers. Ken Kaitin and Christopher Milne at the Tufts
Lundbeck forges CNS pact with Zenobia, Vernalis
Denmark's Lundbeck has forged development pacts with Vernalis as well as Zenobia Therapeutics on an brain enzyme inhibition program designed to target CNS (central nervous system) ailments such as
Alliance targets CNS imaging
E-Clinical solutions provider Perceptive Informatics says it has joined with Biospective to enhance its capabilities for processing and analysis of medical images for central nervous system (CNS) and
Biovail hoards cash for new CNS deals
Canada's Biovail laid the groundwork today for a new round of acquisitions , slashing its dividend by 76 percent is it hoards cash for deals. The dividend move will provide $180 million a year for new
Silicon chips offer new tool to repair nerve damage
Researchers at Edinburgh University have grown neurons, the basic cells of the nervous system, on silicon chips. And the process could eventually serve as a radical new approach to repairing damaged
ALSO NOTED: Novartis buys bigger stake in Alnylam; FDA chastises ZymoGenetics' marketing campaign;and much more...
> Novartis has scooped up a bigger share of Alnylam stock. The pharma giant now owns 13.3 percent of the company.
Emerging Drug Developer: BrainCells
BrainCells Remember when they used to say that you'd have all the brain cells you ever could have when you reached adulthood? Turns
Q Therapeutics raises $15M
Salt Lake City-based Q Therapeutics has raised $15 million in a second round of financing. The company is developing cell-based therapies for the central nervous system. It is currently running
Valeant shares jump on epilepsy trial data
Shares of Valeant Pharma jumped yesterday after the developer announced that its experimental epilepsy treatment retigabine met its primary endpoint in reducing the number of seizures by a
ALSO NOTED: Dynogen goes public; Alpharma sells ingredients unit for $395M; Arizona launches new venture fund; and much more...
> Dynogen Pharmaceuticals is going public in a buyout deal with Apex Bioventures Acquisition Corp. Dynogen shareholders will initially receive $98 million in the deal, with Dynogen merging with a
